多柔比星联合达沙替尼协同抗肿瘤细胞活性的研究

Synergistic Anti-tumor Effects of Doxorubicin Combined with Dasatinib

目的研究多柔比星与达沙替尼联合用药,抑制肿瘤细胞增殖的协同抗肿瘤活性。方法采用MTT法研究多柔比星、达沙替尼单用以及两者联合用药分别对小鼠转移性乳腺癌4T1.2细胞株、人前列腺癌PC3细胞株、人肝癌HepG2细胞株、人结肠癌HCT-116细胞株的细胞增殖抑制率,并计算出相应的半数抑制浓度值及联用指数,评价多柔比星和达沙替尼的抗肿瘤活性和其联合用药的协同作用。结果多柔比星和达沙替尼联合用药抑制4T1.2、PC3、HepG2和HCT-116细胞增殖显著强于多柔比星和达沙替尼分别单用抑制细胞增殖的作用。多柔比星和达沙替尼联合用于4T1.2和PC3细胞的联用指数最低,具有高度的协同效应。结论多柔比星与达沙替尼联用,具有高效抑制4T1.2、PC3、HepG2和HCT-116肿瘤细胞增殖的协同作用。

Objective To study the synergistic anti-tumor effects of doxorubicin combined with dasatinib.Methods MTT assay was used to study the inhibitory rate of cell proliferation of mouse metastatic breast cancer cell line 4 T1.2,human prostate cancer cell line PC3,human liver cancer HepG2 cell line and human colon cancer HCT-116 cell line by doxorubicin,dasartinib alone and doxorubicin combined with dasartinib,and the corresponding half inhibitory concentration was calculated. The antitumor activity of doxorubicin and dasartinib and the synergistic effect of their combination were evaluated. Results The proliferation inhibition of doxorubicin and dasatinib combo against 4 T1.2,PC3,HepG2 and HCT-116 cell lines was more active than doxorubicin and dasatinib treated alone. The combination of doxorubicin and dasatinib treated against 4 T1.2 and PC3 cells showed stronger synergy effect on proliferation inhibition. Conclusion Doxorubicin combining with dasatinib showed significant synergistic effect on tumor cell proliferation effect in 4 T1.2,PC3,HepG2 and HCT-116 cell lines.